Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
ophthalmic solution
|
| gptkbp:activeDuring |
gptkb:bromfenac
|
| gptkbp:administrativeDivision |
twice daily
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
multiple countries
|
| gptkbp:availableSizes |
5 mL bottle
|
| gptkbp:brand |
gptkb:Prolensa
|
| gptkbp:clinicalTrials |
Phase 3
ophthalmology effective in reducing inflammation recommended for postoperative care surgery-related inflammation |
| gptkbp:contraindication |
headache
pregnancy dry eye lactation foreign body sensation hypersensitivity_to_bromfenac |
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
true
available online minimal nonsteroidal anti-inflammatory drug rapid absorption |
| gptkbp:expirationDate |
24 months
|
| gptkbp:formulation |
sterile solution
0.07% solution |
| gptkbp:hasCapacity |
surgical patients
available through manufacturer |
| gptkbp:healthcare |
avoid touching dropper tip
|
| https://www.w3.org/2000/01/rdf-schema#label |
Prolensa
|
| gptkbp:impact |
up to 14 days
|
| gptkbp:issuedBy |
eye drops
|
| gptkbp:lastProduced |
2015
|
| gptkbp:manufacturer |
gptkb:Bausch_+_Lomb
|
| gptkbp:marketedAs |
anti-inflammatory eye drop
|
| gptkbp:marketSegment |
ongoing
|
| gptkbp:numberOfStudents |
approximately 1.5 hours
|
| gptkbp:nutritionalValue |
hepatic
|
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:packaging |
bottle
|
| gptkbp:provides |
postoperative inflammation
|
| gptkbp:relatedTo |
NSAIDs
|
| gptkbp:route |
topical
|
| gptkbp:safetyFeatures |
generally well tolerated
conducted in 2014 |
| gptkbp:sideEffect |
stinging
eye irritation burning sensation |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
adults
|
| gptkbp:triggerType |
inhibition of cyclooxygenase
|
| gptkbp:usedFor |
treatment of inflammation
|